Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era.

ABSTRACT: The ability to stratify patients using a set of biomarkers, which predict that toxicity risk would allow for radiotherapy (RT) modulation and serve as a valuable tool for precision medicine and personalized RT. For patients presenting with tumors with a low risk of recurrence, modifying RT schedules to avoid toxicity would be clinically advantageous. Indeed, for the patient at low risk of developing radiation-associated toxicity, use of a hypofractionated protocol could be proposed leading to treatment time reduction and a cost-utility advantage. Conversely, for patients predicted to be at high risk for toxicity, either a more conformal form or a new technique of RT, or a multidisciplinary approach employing surgery could be included in the trial design to avoid or mitigate RT when the pot

SUBMITTER: Azria D 

PROVIDER: S-EPMC5406456 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature